

CARE Checklist of information to include when writing a case report





troduction atient Information be Primary concerns and symptoms of the patient. be Relevant past interventions with outcomes. concerns and current information information from this episode of care organized as a timeline information assessment by Diagnostic challenges (such as staging in oncology) where applicable by Prognosis (such as staging in oncology) where applicable conclusion and patient-assessed outcomes (ff available). conclusion what is unique about this case and what does it add to the scientific literature? Line 37-39, 47-50 Line 43-45 Line 43-45 Line 43-45 Line 37-38 Line 37-38 Line 37-38 Line 43-45 Line 37-38 Line 43-45 Line 43-45 Line 43-45 Line 43-45 Line 43-45 Line 43-45 Line 47-50 Line 66-69 Line 66-69 Line 67-78 Line 76-78 Experiments of the patient. Line 76-78 Line 76-78 Line 76-78 Line 88-100, 110-11 Line 88-100, 110-11 Line 88-100, 110-11 Line 88-101 Line 112-113 Line 112-113 Line 112-113 Changes in therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) Line 112-113 Changes in therapeutic intervention (such as dosage, strength, duration) Line 112-113 Clinician and patient-assessed outcomes (if available). Line 112-113	Topic	Item	Checklist item description	Reported on Line
Introduction: What is unique about this case and what does it add to the scientific literature? In a 37-39, 47-50 In a 38-39, 47-50 In a 37-39, 47-50 In a 4 Secultion—In a 37-39, 47-50 In a 4 Secultion—In a 4 Secultion—In a 4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4	Γitle	1	The diagnosis or intervention of primary focus followed by the words "case report"	Line1-2
No references) 3b Main symptoms and/or important clinical findings	ey Words	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	Line 51
The main diagnoses, therapeutic interventions, and outcomes	Abstract (no references)	3a	Introduction: What is unique about this case and what does it add to the scientific literature?	Line 37-39、47-50
troduction 4 One or two paragraphs summarizing why this case is unique (may include references) Line 62-69 attent Information 5a De-identified patient specific information. Line 75-76 5b Primary concerns and symptoms of the patient. Line 76-78 Line 76-78 6c Medical, family, and psycho-social history including relevant genetic information. Line 86-68 Line 98-100, 110-11 linical Findings 6 Describe significant physical examination (PE) and important clinical findings Line 80-85, 88-90 linical Findings 7 Historical and current information from this episode of care organized as a timeline 8b Diagnostic testing (such as PE, laboratory testing, imaging, surveys). Line 88-101 Line 98-101, 107-109 linical Findings 8c Diagnostic challenges (such as access to testing, financial, or cultural) Line98-101,107-109, 116-84 Prognosis (including other diagnoses considered) Line107-109, 116-84 Prognosis (such as staging in oncology) where applicable N/A dministration of therapeutic intervention (such as dosage, strength, duration) Line 112-113 9b Administration of therapeutic intervention (such as dosage, strength, duration) Line 112-113 108-1010-1010-1010-1010-1010-1010-1010-		3b	Main symptoms and/or important clinical findings	Line 43-45
troduction 4 One or two paragraphs summarizing why this case is unique (may include references) Line 62-69 atient Information 5 De-identified patient specific information. Line 75-76 b Primary concerns and symptoms of the patient. Line 76-78 Experiment of Relevant past interventions with outcomes Line 98-100. 110-11 inical Findings 6 Describe significant physical examination (PE) and important clinical findings. Line 80-85, 88-90 Historical and current information from this episode of care organized as a timeline Line 75-77, 112-113, 117- agnostic 8 Diagnostic testing (such as PE, laboratory testing, imaging, surveys). Line 88-101 Line 98-101, 107-109, 116- 8b Diagnostic challenges (such as access to testing, financial, or cultural) Line 98-101,107-109, 116- 8c Diagnosis (including other diagnoses considered) Line 107-109, 116- 8d Prognosis (such as staging in oncology) where applicable N/A Prognosis (such as staging in oncology) where applicable N/A Administration of therapeutic intervention (such as dosage, strength, duration) Line 112-113 9c Changes in therapeutic intervention (such as dosage, strength, duration) Line 114-119 cline 114-119 Line 114-119 Line 114-119 Line 112-113 Adverse and unanticipated events N/A Line 122-123 N/A Adverse and unanticipated events N/A Line 122-121 Line 203-211, 214-217 Line 217-221 Line 217-221 Line 217-221 Line 217-2210 Line 217-2210		3c	The main diagnoses, therapeutic interventions, and outcomes	Line 37-38
atient Information 5a De-identified patient specific information. Line 75-76 5b Primary concerns and symptoms of the patient. Line 76-78 5c Medical, family, and psycho-social history including relevant genetic information Line 66-68 5d Relevant past interventions with outcomes Line 98-100, 110-11 inical Findings 6 Describe significant physical examination (PE) and important clinical findings Line 80-85, 88-90 meline 7 Historical and current information from this episode of care organized as a timeline Line 75-77, 112-1113, 117- agnostic 8a Diagnostic testing (such as PE, laboratory testing, imaging, surveys). Line 88-101 Sb Diagnostic challenges (such as access to testing, financial, or cultural) Line98-101,107-109, 116- 8d Prognosis (including other diagnoses considered) Line107-109, 116- 8d Prognosis (such as staging in oncology) where applicable N/A Prerepeutic 9a Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) Line 112-113 9c Changes in therapeutic intervention (such as dosage, strength, duration) Line 112-113 9c Changes in therapeutic intervention (with rationale) Line 114-119 stroman 10a Clinician and patient-assessed outcomes (if available) Line 114-119 10b Important follow-up diagnostic and other test results Line 112-123 10c Intervention adherence and tolerability (How was this assessed?) Line 122-123 10d Adverse and unanticipated events N/A 11a A scientific discussion of the strengths AND limitations associated with this case report Line 217-221 11b Discussion of the relevant medical literature with references. Line 217-221 11c The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion Line 272-280 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion. Line 272-280		3d	Conclusion—What is the main "take-away" lesson(s) from this case?	Line47-50
Sb Primary concerns and symptoms of the patient. Line 76-78	troduction	4	One or two paragraphs summarizing why this case is unique (may include references)	Line 62-69
Sc Medical, family, and psycho-social history including relevant genetic information Line 66-68	Patient Information	5a	De-identified patient specific information	Line 75-76
Relevant past interventions with outcomes		5b	Primary concerns and symptoms of the patient	Line 76-78
inical Findings 6 Describe significant physical examination (PE) and important clinical findings. Line 80-85, 88-90 Historical and current information from this episode of care organized as a timeline Jiagnostic as Diagnostic testing (such as PE, laboratory testing, imaging, surveys). Line 88-101 Line 98-101,107-109, 116- Ba Diagnostic challenges (such as access to testing, financial, or cultural). Line 98-101,107-109, 116- Ba Diagnosis (including other diagnoses considered). Line 107-109, 116- Ba Prognosis (such as staging in oncology) where applicable. N/A Perapeutic arrepeutic parapeutic intervention (such as pharmacologic, surgical, preventive, self-care). Line 112-113 Changes in therapeutic intervention (such as dosage, strength, duration). Line 112-113 Changes in therapeutic intervention (with rationale). Line 114-119 Dillow-up and attromes Intervention adherence and tolerability (How was this assessed?). Line 117-118 Line 119-122 Line 119-122 Line 112-123 Adverse and unanticipated events. N/A Scussion Intervention adherence and tolerability (How was this assessed?). Line 217-221 Line 217-221 Line 217-221 The Discussion of the relevant medical literature with references. Line 214-217 Line 214-217 Line 214-217 Line 214-219, 248-25 Line 214-219, 248-25 Line 214-219, 248-25 Line 217-2280 Attent Perspective The patient should share their perspective in one to two paragraphs on the treatment(s) they received. N/A		5c	Medical, family, and psycho-social history including relevant genetic information	Line 66-68
### Historical and current information from this episode of care organized as a timeline Line 75-77, 112-113, 117- ### agnostic seesment 8a		5d	Relevant past interventions with outcomes	Line 98-100、110-11
agnostic ssessment 8a Diagnostic testing (such as PE, laboratory testing, imaging, surveys). 1biagnostic challenges (such as access to testing, financial, or cultural). 1cine98-101,107-109. 1cine107-109. 116- 8d Prognosis (such as staging in oncology) where applicable. 1cine107-109. 116- 8d Prognosis (such as staging in oncology) where applicable. 1cine112-113. 1cine 112-113. 1cine 112	inical Findings	6	Describe significant physical examination (PE) and important clinical findings	Line 80-85、88-90
agnostic seesament 8a Diagnostic testing (such as PE, laboratory testing, imaging, surveys). Line 88-101 Line 98-101,107-109. 8b Diagnostic challenges (such as access to testing, financial, or cultural). Line98-101,107-109. 116- 8d Prognosis (such as staging in oncology) where applicable. N/A Prognosis (such as staging in oncology) where applicable. N/A Prognosis (such as staging in oncology) where applicable. N/A Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care). Line 112-113 9c Changes in therapeutic intervention (such as dosage, strength, duration). Line 112-113 9c Changes in therapeutic intervention (with rationale). Line 114-119 9dllow-up and load Clinician and patient-assessed outcomes (if available). Line 117-118 10b Important follow-up diagnostic and other test results. Line119-122 10c Intervention adherence and tolerability (How was this assessed?). Line 122-123 10d Adverse and unanticipated events. N/A 11a A scientific discussion of the strengths AND limitations associated with this case report. Line 217-221 11b Discussion of the relevant medical literature with references. Line208-211, 214-217 11c The scientific rationale for any conclusions (including assessment of possible causes). Line 214-219, 248-25 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion. Line 272-280 attent Perspective 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received. N/A	meline	7	Historical and current information from this episode of care organized as a timeline	e75-77、112-113、117-
Diagnostic challenges (such as access to testing, financial, or cultural). Line107-109. 116- Recompleted the Prognosis (such as staging in oncology) where applicable. N/A Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care). Line 112-113 9c Changes in therapeutic intervention (such as dosage, strength, duration). Line 114-119 Illine 114-119 Illine 117-118 Illine 117-118 Illine 117-118 Important follow-up diagnostic and other test results. Line 119-122 Intervention adherence and tolerability (How was this assessed?). Line 122-123 N/A A scientific discussion of the strengths AND limitations associated with this case report. Line 217-221 Line 217-221 Line 218-211. Line 218-211. Line 218-211. Line 219. 248-25. Line 214-219. 248-25. Line 272-280 The patient should share their perspective in one to two paragraphs on the treatment(s) they received. N/A Line 272-280	Diagnostic Assessment	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys)	Line 88-101
Recapeutic tervention 9a Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) 1b Administration of therapeutic intervention (such as dosage, strength, duration) 1c Changes in therapeutic intervention (with rationale) 1c Changes in therapeutic intervention (with rationale) 1c Clinician and patient-assessed outcomes (if available) 1c Intervention adherence and tolerability (How was this assessed?) 1c Intervention adherence and tolerability (How was this assessed?) 1c Intervention adherence and tolerability (How was this assessed?) 1c A scientific discussion of the strengths AND limitations associated with this case report 1c The scientific rationale for any conclusions (including assessment of possible causes) 1c The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 1c The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 1c The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 1c Ine 217-2280 N/A 1c The patient should share their perspective in one to two paragraphs on the treatment(s) they received.		8b	Diagnostic challenges (such as access to testing, financial, or cultural)	Line98-101,107-109.
Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) Administration of therapeutic intervention (such as dosage, strength, duration) Changes in therapeutic intervention (with rationale) Changes in therapeutic intervention (with rationale) Line 112-113 Changes in therapeutic intervention (with rationale) Line 114-119 Line 117-118 Line 121-122 Line 122-123 N/A Adverse and unanticipated events Scussion Line 217-221 Line 217-221 Line 208-211, 214-217 Line 208-211, 214-217 The scientific rationale for any conclusions (including assessment of possible causes) Line 214-219, 248-25 Line 272-280 Attent Perspective The patient should share their perspective in one to two paragraphs on the treatment(s) they received. N/A		8c		1 ! 407 400 440
tervention 9b Administration of therapeutic intervention (such as dosage, strength, duration) 10c Changes in therapeutic intervention (with rationale) 10a Clinician and patient-assessed outcomes (if available) 10b Important follow-up diagnostic and other test results 10c Intervention adherence and tolerability (How was this assessed?) 10d Adverse and unanticipated events 11d A scientific discussion of the strengths AND limitations associated with this case report 11d The scientific rationale for any conclusions (including assessment of possible causes) 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received N/A Line 112-113 Line 112-115 Line 112-113 Line 114-119 Line 114-119 Line 117-118 Line 117-118		8d	Prognosis (such as staging in oncology) where applicable	N/A
Changes in therapeutic intervention (with rationale) 10a Clinician and patient-assessed outcomes (if available). 10b Important follow-up diagnostic and other test results 10c Intervention adherence and tolerability (How was this assessed?). 10d Adverse and unanticipated events. 11d A scientific discussion of the strengths AND limitations associated with this case report. 11b Discussion of the relevant medical literature with references. 11c The scientific rationale for any conclusions (including assessment of possible causes). 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion. 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 11d N/A 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 11d N/A	Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	Line 112-113
10a Clinician and patient-assessed outcomes (if available). 10b Important follow-up diagnostic and other test results 10c Intervention adherence and tolerability (How was this assessed?). 10d Adverse and unanticipated events 11a A scientific discussion of the strengths AND limitations associated with this case report. 11b Discussion of the relevant medical literature with references. 11c The scientific rationale for any conclusions (including assessment of possible causes). 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion. 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 11d N/A 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received.		9b	Administration of therapeutic intervention (such as dosage, strength, duration)	Line 112-113
Important follow-up diagnostic and other test results Intervention adherence and tolerability (How was this assessed?) Intervention adherence and unanticipated events Intervention adherence and una		9с	Changes in therapeutic intervention (with rationale)	Line 114-119
Intervention adherence and tolerability (How was this assessed?) 10c Intervention adherence and tolerability (How was this assessed?) 10d Adverse and unanticipated events 11a A scientific discussion of the strengths AND limitations associated with this case report 11b Discussion of the relevant medical literature with references. 11c The scientific rationale for any conclusions (including assessment of possible causes) 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 13 Intervention adherence and tolerability (How was this assessed?) 14 Line 122-123 15 Line 217-221 16 Line 217-221 17 Line 214-219 17 Line 214-219 18 Line 272-280 19 Line 272-280 10 N/A	Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available)	Line 117-118
Adverse and unanticipated events		10b	Important follow-up diagnostic and other test results	Line119-122
A scientific discussion of the strengths AND limitations associated with this case report. Line 217-221 Line 208-211、214-217 In patient Should share their perspective in one to two paragraphs on the treatment(s) they received. Line 217-221 Line 217-221 Line 217-221 Line 218-217 Line 218-218 Line 218-		10c	Intervention adherence and tolerability (How was this assessed?)	Line 122-123
11b Discussion of the relevant medical literature with references. 11c The scientific rationale for any conclusions (including assessment of possible causes). 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion. 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received. 13 The patient should share their perspective in one to two paragraphs on the treatment(s) they received.		10d	Adverse and unanticipated events	N/A
11c The scientific rationale for any conclusions (including assessment of possible causes)	Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report	Line 217-221
The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion Line 272-280 The patient should share their perspective in one to two paragraphs on the treatment(s) they received		11b	Discussion of the relevant medical literature with references.	Line208-211、214-217
The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion Line 272-280 The patient should share their perspective in one to two paragraphs on the treatment(s) they received		11c	The scientific rationale for any conclusions (including assessment of possible causes)	Line 214-219、248-25
The patient discharge from the transfer of the treatment		11d		
Iformed Consent 13 Did the patient give informed consent? Please provide if requested	atient Perspective	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received	N/A
	formed Consent	13	Did the patient give informed consent? Please provide if requested	Yes 🗌 No 🔽